White House says Johnson & Johnson pause won't affect federal vaccination plan

The White House does not appear to be concerned about whether the Food and Drug Administration's recommendation to pause the use of the Johnson & Johnson COVID-19 vaccine may hinder its distribution strategy.
Jeff Zients, the White House coronavirus response coordinator, said in a statement Tuesday that because the Johnson & Johnson vaccine makes up only a small percentage of the recorded shots in the U.S., the federal plan should remain intact without any major hiccups. "Over the last few weeks, we have made available more than 25 million doses of Pfizer and Moderna [vaccines] each week ... This is more than enough supply to continue the current pace of 3 million shots per day, and meet [President Biden's] goal of 200 million shots by his 100th day in office," the statement said.
Johnson & Johnson appointments scheduled for the next several days have already been canceled, but Zients said the Biden administration is working with state and federal partners to reschedule those for a dose of Pfizer or Moderna.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
While the math may hold up for the White House's goals, there are still other factors to consider, including whether the FDA's decision leads to any noticeable increase in vaccine hesitancy, regardless of which shots are available.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published